The European Commission (EC) has approved a new Opdivo (nivolumab) formulation associated with a new route of administration ...

An oncology nurse shares advice for avoiding exhaustion and soreness when administering subcutaneous injections.

Bristol Myers Squibb receives European approval for subcutaneous formulation of Opdivo across multiple solid tumour indications: Princeton, New Jersey Thursday, May 29, 2025, 15:0 ...

The EC has granted approval for the new subcutaneous (SC) formulation of Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) ...

The US Food and Drug Administration (FDA) has accepted Otsuka Pharmaceutical’s biologics licence application for ...

Bristol Myers Squibb's Opdivo has been approved in a subcutaneous injection formulation by the FDA, making treatment easier for patients and potentially adding years to the product's patent life.

A formulation of MSD's cancer drug Keytruda that can be given by subcutaneous injection rather than intravenous infusion has cleared a phase 3 trial, setting up approvals later this year.

CeleCor Therapeutics has completed its multinational Phase 3 clinical trial of Disaggpro™ (zalunfiban), an investigational heart-attack drug designed for rapid use at first point of medical contact – ...

Japanese drugmaker Otsuka Pharmaceutical (TYO: 4578) today announced the US Food and Drug Administration (FDA) has accepted ...

Market LaunchFormycon and Fresenius Kabi announce the commercial launch of FYB202/Otulfi™, an approved ustekinumab biosimilar in Canada 27.05.2025 / 14:30 CET/CESTThe issuer is solely responsible for ...